“Kulkarni and colleagues conducted a 12-week randomized, double-blind, placebo-controlled trial of raloxifene—given as an adjunct to antipsychotics—versus adjunctive placebo in Australia. The authors hypothesized that 120 mg/d of adjunctive raloxifene would improve both refractory symptoms and cognition in women with schizophrenia.”
http://www.psychiatrictimes.com/schizophrenia/adjunctive-raloxifene-women-schizophrenia